These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28302407)

  • 41. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
    Schuind A; Segall N; Drame M; Innis BL
    J Infect Dis; 2015 Aug; 212(4):531-41. PubMed ID: 25722291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
    Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
    Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.
    Rümke HC; Richardus JH; Rombo L; Pauksens K; Plaßmann G; Durand C; Devaster JM; Dewé W; Oostvogels L
    BMC Infect Dis; 2013 Jul; 13():348. PubMed ID: 23890405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
    Langley JM; Frenette L; Chu L; McNeil S; Halperin S; Li P; Vaughn D
    BMC Infect Dis; 2012 Oct; 12():279. PubMed ID: 23110320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Ortiz JR; Spearman PW; Goepfert PA; Cross K; Buddy Creech C; Chen WH; Parker S; Overton ET; Dickey M; Logan HL; Wegel A; Neuzil KM
    Vaccine; 2022 May; 40(23):3253-3262. PubMed ID: 35465983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
    Vanni T; Thomé BC; Sparrow E; Friede M; Fox CB; Beckmann AM; Huynh C; Mondini G; Silveira DH; Viscondi JYK; Braga PE; Silva AD; Salomão MDG; Piorelli RO; Santos JP; Gattás VL; Lucchesi MBB; Oliveira MMM; Koike ME; Kallas EG; Campos LMA; Coelho EB; Siqueira MAM; Garcia CC; Miranda MD; Paiva TM; Timenetsky MDCST; Adami EA; Akamatsu MA; Ho PL; Precioso AR
    PLoS One; 2022; 17(10):e0274943. PubMed ID: 36256646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
    Naruse T; Fukuda T; Tanabe T; Ichikawa M; Oda Y; Tochihara S; Kimachi K; Kino Y; Ueda K
    Vaccine; 2015 Nov; 33(45):6078-84. PubMed ID: 26409141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.
    Scheifele DW; Dionne M; Ward BJ; Cooper C; Vanderkooi OG; Li Y; Halperin SA;
    Hum Vaccin Immunother; 2013 Jan; 9(1):136-43. PubMed ID: 23570051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
    Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
    Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
    Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
    McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
    Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
    Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ
    BMJ; 2010 May; 340():c2649. PubMed ID: 20508026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.